Progyny Dirección
Dirección controles de criterios 4/4
El CEO de Progyny's es Pete Anevski , nombrado en Jan 2022, tiene una permanencia de 2.25 años. compensación anual total es $1.09M, compuesta por 45.7% salario y 54.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.014% de las acciones de la empresa, por valor de $438.76K. La antigüedad media del equipo directivo y de la junta directiva es de 2.3 años y 7.1 años, respectivamente.
Información clave
Pete Anevski
Chief Executive Officer (CEO)
US$1.1m
Compensación total
| Porcentaje del salario del CEO | 45.7% |
| Permanencia del CEO | 2.3yrs |
| Participación del CEO | 0.01% |
| Permanencia media de la dirección | 2.3yrs |
| Promedio de permanencia en la Junta Directiva | 7.1yrs |
Actualizaciones recientes de la dirección
Recent updates
Why We're Not Concerned About Progyny, Inc.'s (NASDAQ:PGNY) Share Price
Apr 29
Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?
Apr 03Progyny: Long-Term Outlook Remains Positive, Reiterate Buy
Mar 15Progyny: Long-Term Thesis Still Intact
Mar 09Progyny's (NASDAQ:PGNY) Returns On Capital Are Heading Higher
Mar 01Progyny, Inc.'s (NASDAQ:PGNY) P/E Still Appears To Be Reasonable
Jan 07Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?
Dec 11Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)
Nov 08Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?
Aug 24There's Been No Shortage Of Growth Recently For Progyny's (NASDAQ:PGNY) Returns On Capital
Aug 06Progyny (NASDAQ:PGNY) Is Looking To Continue Growing Its Returns On Capital
May 06When Should You Buy Progyny, Inc. (NASDAQ:PGNY)?
Jan 25Progyny (NASDAQ:PGNY) Shareholders Will Want The ROCE Trajectory To Continue
Dec 12Is It Time To Consider Buying Progyny, Inc. (NASDAQ:PGNY)?
Oct 18Progyny Stock Should Deliver Superior Returns For Investors
Aug 05Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)
Jul 27At US$31.63, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?
Jul 08Progyny: Solving Infertility Problem
Jul 05Progyny Stock: A Hidden Gem Tackling Infertility
May 31Investors Will Want Progyny's (NASDAQ:PGNY) Growth In ROCE To Persist
Apr 18At US$50.90, Is It Time To Put Progyny, Inc. (NASDAQ:PGNY) On Your Watch List?
Mar 31Earnings Not Telling The Story For Progyny, Inc. (NASDAQ:PGNY)
Mar 18Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | US$1m | US$500k | US$62m |
| Sep 30 2023 | n/a | n/a | US$52m |
| Jun 30 2023 | n/a | n/a | US$49m |
| Mar 31 2023 | n/a | n/a | US$43m |
| Dec 31 2022 | US$69m | US$500k | US$30m |
| Sep 30 2022 | n/a | n/a | US$42m |
| Jun 30 2022 | n/a | n/a | US$46m |
| Mar 31 2022 | n/a | n/a | US$56m |
| Dec 31 2021 | US$786k | US$425k | US$66m |
| Sep 30 2021 | n/a | n/a | US$90m |
| Jun 30 2021 | n/a | n/a | US$78m |
| Mar 31 2021 | n/a | n/a | US$58m |
| Dec 31 2020 | US$910k | US$425k | US$46m |
| Sep 30 2020 | n/a | n/a | US$3m |
| Jun 30 2020 | n/a | n/a | -US$10m |
| Mar 31 2020 | n/a | n/a | -US$5m |
| Dec 31 2019 | US$5m | US$375k | -US$9m |
| Sep 30 2019 | n/a | n/a | -US$6m |
| Jun 30 2019 | n/a | n/a | US$1m |
| Mar 31 2019 | n/a | n/a | -US$4m |
| Dec 31 2018 | US$682k | US$325k | -US$6m |
Compensación vs. Mercado: La compensación total de Pete($USD1.09M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD6.59M).
Compensación vs. Ingresos: La compensación de Pete ha sido consistente con los resultados de la empresa en el último año.
CEO
Pete Anevski (56 yo)
2.3yrs
Permanencia
US$1,093,512
Compensación
Mr. Peter Anevski, also known as Pete, has been Chief Executive Officer and Director of Progyny, Inc. since January 2022 and had been its President since June 2019 until December 31, 2021 and was its Chief...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman | 7.1yrs | US$513.57k | 0.0056% $ 172.4k | |
| CEO & Director | 2.3yrs | US$1.09m | 0.014% $ 433.9k | |
| President | 2.3yrs | US$1.49m | 0.066% $ 2.0m | |
| Chief Financial Officer | 3.6yrs | US$1.40m | 0% $ 0 | |
| Executive VP | 1.4yrs | US$546.22k | 0.012% $ 379.1k | |
| Chief Technology Officer | less than a year | sin datos | sin datos | |
| Vice President of Investor Relations | no data | sin datos | sin datos | |
| Chief Marketing Officer | no data | sin datos | sin datos | |
| Chief Human Resources Officer | no data | sin datos | sin datos | |
| Chief Business Development Officer | 2.3yrs | sin datos | sin datos | |
| Member of the Medical Advisory Board & Chief Medical Officer | less than a year | sin datos | sin datos | |
| Senior Vice President of Employer Market Strategy | 1.9yrs | sin datos | sin datos |
2.3yrs
Permanencia media
56yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de PGNY se considera experimentado (2.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman | 7.1yrs | US$513.57k | 0.0056% $ 172.4k | |
| CEO & Director | 2.3yrs | US$1.09m | 0.014% $ 433.9k | |
| Member of the Medical Advisory Board & Chief Medical Officer | no data | sin datos | sin datos | |
| Independent Director | 7.3yrs | US$567.30k | 0.42% $ 13.0m | |
| Independent Director | 9.1yrs | US$583.35k | 0.013% $ 388.6k | |
| Lead Independent Director | 13.9yrs | US$653.39k | 0.27% $ 8.3m | |
| Independent Director | 4.5yrs | US$518.30k | 0.0065% $ 198.6k | |
| Independent Director | 4.5yrs | US$606.88k | 0.013% $ 388.6k | |
| Member of the Medical Advisory Board | no data | sin datos | sin datos | |
| Member of Medical Advisory Board | no data | sin datos | sin datos | |
| Member of Medical Advisory Board | no data | sin datos | sin datos | |
| Member of Medical Advisory Board | no data | sin datos | sin datos |
7.1yrs
Permanencia media
64yo
Promedio de edad
Junta con experiencia: La junta directiva de PGNY se considera experimentada (7.1 años de antigüedad promedio).